ERBB2 and breast cancer: T-DM1 has an average DAR of 3.5 compared to an average of 8 for T-DXd.2 T-DXd has demonstrated efficacy in HER2 progressing on T-DM1 and has been shown to be effective and also approved for the treatment of breast cancer patients with low HER2 expression.18,20